Insights into the Currently Available Drugs and Investigational Compounds Against RSV with a Focus on Their Drug-Resistance Profiles
Viruses · 2025
DOI: 10.3390/v17060793 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, 2025. Verfasst von Alessia Magnapera und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, University of Rome Tor Vergata, 00133 Rome, Italy. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Drug Resistance, Viral, Antiviral Agents, Respiratory Syncytial Virus, Human. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Respiratory syncytial virus (RSV) is a leading cause of severe respiratory illness in infants, young children, as well as elderly and immunocompromised patients worldwide. RSV is classified into two major subtypes, RSV-A and RSV-B, and remains the most frequently detected pathogen in infants hospitalized with acute respiratory infections. Recent advances have brought both passive and active immunization strategies, including FDA-approved vaccines for older adults and pregnant women and new monoclonal antibodies (mAbs) for infant protection. Although significant progress has been made, the need remains for improved antiviral treatments, particularly for vulnerable infants and immunocompromised patients. Recent studies have identified multiple RSV mutations that confer resistance to current treatments. These mutations, detected in both in vitro studies and clinical isolates, often complicate therapeutic outcomes, underscoring the need for updated and effective management strategies. In this context, evaluating protein flexibility through tools like DisoMine provides insight into how specific mutations impact structural dynamics at binding sites, thus affecting ligand affinity. This review aims to synthesize these aspects, offering a comprehensive insight into ongoing efforts to counteract RSV and address the evolving challenge of drug resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, University of Rome Tor Vergata, 00133 Rome, Italy.
- Department of Health Science, Magna Graecia University, 88100 Catanzaro, Italy.
- Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.
- Microbiology and Virology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
ORCID-Profile: Alessia Magnapera, Anna Riccio, Antonio Curcio, Lorenzo Piermatteo, Stefano D'Anna, Stefano Alcaro, Anna Artese, Romina Salpini
Zitieren
APA
Magnapera, A., Riccio, A., Curcio, A., Tramontozzi, C., Piermatteo, L., D'Anna, S., Alcaro, S., Alteri, C., La Frazia, S., Artese, A., Salpini, R., & Svicher, V. (2025). Insights into the Currently Available Drugs and Investigational Compounds Against RSV with a Focus on Their Drug-Resistance Profiles. Viruses. https://doi.org/10.3390/v17060793
Vancouver
Magnapera A, Riccio A, Curcio A, Tramontozzi C, Piermatteo L, D'Anna S, et al. Insights into the Currently Available Drugs and Investigational Compounds Against RSV with a Focus on Their Drug-Resistance Profiles. Viruses. 2025. doi:10.3390/v17060793
BibTeX
@article{Magnapera2025,
author = {Magnapera, Alessia and Riccio, Anna and Curcio, Antonio and Tramontozzi, Caterina and Piermatteo, Lorenzo and D'Anna, Stefano and Alcaro, Stefano and Alteri, Claudia and La Frazia, Simone and Artese, Anna and Salpini, Romina and Svicher, Valentina},
title = {Insights into the Currently Available Drugs and Investigational Compounds Against RSV with a Focus on Their Drug-Resistance Profiles},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17060793}
}
EUVIMED